• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

COVID-19 adenoviral but not mRNA vaccines are associated with adverse cardiovascular events

byBryant LimandKiera Liblik
September 5, 2022
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The first dose of adenoviral-based Oxford-AstraZeneca and Janssen vaccines was associated with acute myocardial infarction and pulmonary embolism.

2. mRNA-based Pfizer-BioNTech and Moderna vaccines were not associated with severe cardiovascular events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Adenoviral-based (ChAdOx1 nCoV-19 [Oxford–AstraZeneca] and Ad26.COV2.S [Janssen]) and mRNA-based (BNT162b2 [Pfizer–BioNTech] and mRNA-1273 [Moderna]) vaccines have been authorized for the general population to reduce coronavirus disease 2019 (COVID-19) infections. However, numerous studies have revealed unintended associations between vaccination and severe cardiovascular side effects. The present self-controlled case series (SCCS) study used data from the French National Health Data System and COVID-19 vaccine databases to determine the association of the Oxford-AstraZeneca, Janssen, Pfizer-BioNTech, and Moderna vaccines with hospitalization due to adverse cardiovascular events. Myocardial infarction, stroke, and pulmonary embolism were considered. There were no significant associations between Pfizer-BioNTech and Moderna mRNA-based Covid-19 vaccines and adverse cardiovascular events. The first dose of Janssen adenoviral-based vaccine was associated with an increased incidence of myocardial infarction compared to control periods. There was an increased risk of pulmonary embolism and myocardial infarction after the first dose of the Oxford-AstraZeneca adenoviral-based vaccine. However, the magnitude of these positive associations between adenoviral-based vaccines and cardiovascular events is moderate compared to those related to COVID-19 infection. As a limitation, cardiovascular events in outpatient settings could not be included in the analysis as data was not available.

Click to read the study in AIM

In-Depth [case-control study]: The present case-control study used records from the French National Health Data System and COVID-19 vaccine databases to evaluate the associations between adenoviral-based (ChAdOx1 nCoV-19 [Oxford–AstraZeneca] and Ad26.COV2.S [Janssen]) and mRNA-based (BNT162b2 [Pfizer–BioNTech] and mRNA-1273 [Moderna]) vaccines and adverse cardiovascular events. Outcomes included myocardial infarction, stroke, and pulmonary embolism. Data for all adults aged 18 to 74 were collected from the earliest date of vaccine availability (between December 2020 and April 2021 for various vaccines) to July 2021. A modified version of the SCCS method, where each individual served as their own control, was used to estimate the within-individual relative incidence of cardiovascular events for the first and second doses of the vaccine. The three weeks following each vaccination dose were used to assess risk compared to the same individual’s baseline period prior to vaccination. In total, 73,325 adults experienced cardiovascular events during the study period and were used for analysis. There were no significant associations between the Pfizer-BioNTech and Moderna vaccines and any of the cardiovascular events. For the Janssen vaccine, the incidence of myocardial infarction (2.4 events per 100,000 doses) was increased during the second week after the first dose compared to the control period (Relative Incidence [RI], 1.75; Confidence Interval [CI], 1.16 to 2.62). For the Oxford-AstraZeneca vaccine, the incidence of myocardial infarction (1.3 events per 100,000 doses) was increased during the second week after the first dose (RI, 1.28; CI, 1.12 to 1.47). A similar increase in the incidence of pulmonary embolism (0.7 events per 100,000 doses) was found (RI, 1.30; CI, 1.04 to 1.62). This is the most complete study of the adverse cardiovascular effects of the first and second doses of each vaccine individually. These results may help to inform vaccine choice and public health initiatives to address the cardiovascular effects of COVID-19 vaccines.

Image: PD

RELATED REPORTS

Unvaccinated status increases risk of long COVID symptoms

Combined visual-olfactory training for COVID-19 resultant olfactory loss

2 Minute Medicine Rewind January 23, 2023

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adenovirus vaccineastrazenecacardiovascular adverse eventsCOVID-19COVID-19 Vaccineinfectious diseasejanssenmodernamRNA vaccinemyocardial infarctionpfizerpublic healthpulmonary embolismstroke
Previous Post

#VisualAbstract: Aspirin resulted in higher rate of venous thromboembolism following arthroplasty compared to enoxaparin

Next Post

Aspirin associated with significantly higher rate of symptomatic venous thromboembolism compared to enoxaparin in patients undergoing hip or knee arthroplasty – the CRISTAL randomized trial

RelatedReports

Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
School nurses essential in design and implementation of school safety programs
Chronic Disease

Combined visual-olfactory training for COVID-19 resultant olfactory loss

January 23, 2023
Many new pediatric asthma cases attributable to obesity
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 23, 2023
#VisualAbstract: Treatment with fluvoxamine does not improve time to sustained recovery in outpatients with mild to moderate COVID-19
StudyGraphics

#VisualAbstract: Treatment with fluvoxamine does not improve time to sustained recovery in outpatients with mild to moderate COVID-19

January 23, 2023
Next Post
Patient Basics: Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism)

Aspirin associated with significantly higher rate of symptomatic venous thromboembolism compared to enoxaparin in patients undergoing hip or knee arthroplasty – the CRISTAL randomized trial

Poor olfaction linked to increased mortality in older adults

Nirmatrelvir associated with improved COVID-19 outcomes in older adults

Prenatal antidepressant exposure may increase risk of poor motor development

Risk of gestational diabetes diagnosis significantly increased among individuals with high polygenic risk scores and low levels of physical activity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options